Kurebayashi, Junichi http://orcid.org/0000-0003-0356-842X
Shiba, Eiichi
Toyama, Tatsuya
Matsumoto, Hiroshi
Okazaki, Minoru
Nomizu, Tadashi
Ohtake, Tohru
Fujii, Takaaki
Ohashi, Yasuo
Funding for this research was provided by:
the Comprehensive Support Project for Oncology Research of the Public Health Research Foundation
Takeda Pharmaceutical Company Limited
Article History
Received: 28 July 2020
Accepted: 9 December 2020
First Online: 27 February 2021
Compliance with ethical standards
:
: Dr. Kurebayashi received grants and personal fees from Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., and Chugai Pharmaceutical Co., Ltd., outside the submitted work. Dr. Toyama received personal fees from AstraZeneca K.K., outside the submitted work. Dr. Toyama also received grants and personal fees from Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., Novartis Pharma K.K., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Nippon Kayaku Co., Ltd., and Kyowa Kirin Co., Ltd., outside the submitted work. Prof. Ohashi received grants from Medical Member System, outside the submitted work. Prof. Ohashi also received personal fees from Statcom Company Limited, Daiichi Sankyo Company, Limited, Chugai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Sanofi K.K., and EP-CRSU Co., Ltd., outside the submitted work. The other authors declare that they have no competing interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.